The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice

Mónika Mácsai, Imre Pataki, G. Tóth, Gyula Szabó

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice. The heat-radiant tail-flick test was used to assess antinociceptive threshold. Intracerebroventricular (i.c.v.) administration of PACAP alone had no effect on pain sensitivity but in a dose of 500 ng, it significantly diminished the analgesic effect of a single dose of morphine (2.25 mg/kg, s.c.). PACAP (500 ng, i.c.v.) significantly increased the chronic tolerance to morphine and enhanced the naloxone (1 mg/kg, s.c.)-precipitated withdrawal jumping. Theophylline (1 mg/kg, i.p.) pretreatment significantly enhanced the effect of PACAP on morphine analgesia but the effects of PACAP on tolerance and withdrawal were unaffected upon theophylline administration. On the grounds of our previous studies with vasoactive intestinal polypeptide (VIP), it appears that different receptors are involved in the effects of PACAP in acute and chronic morphine actions. Our results indicate that PACAP-induced actions likely participate in acute and chronic effects of morphine and suggest a potential role of PACAP in opioid analgesia, tolerance and withdrawal.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalRegulatory Peptides
Volume109
Issue number1-3
DOIs
Publication statusPublished - Nov 15 2002

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Morphine
Analgesia
Theophylline
Pain
Vasoactive Intestinal Peptide
Naloxone
Opioid Analgesics
Analgesics
Tail
Hot Temperature

Keywords

  • Analgesia
  • Morphine
  • Mouse
  • PACAP
  • Tolerance
  • Withdrawal

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice. / Mácsai, Mónika; Pataki, Imre; Tóth, G.; Szabó, Gyula.

In: Regulatory Peptides, Vol. 109, No. 1-3, 15.11.2002, p. 57-62.

Research output: Contribution to journalArticle

Mácsai, Mónika ; Pataki, Imre ; Tóth, G. ; Szabó, Gyula. / The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice. In: Regulatory Peptides. 2002 ; Vol. 109, No. 1-3. pp. 57-62.
@article{fce7d8cfba9940cb935090db025d5773,
title = "The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice",
abstract = "The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice. The heat-radiant tail-flick test was used to assess antinociceptive threshold. Intracerebroventricular (i.c.v.) administration of PACAP alone had no effect on pain sensitivity but in a dose of 500 ng, it significantly diminished the analgesic effect of a single dose of morphine (2.25 mg/kg, s.c.). PACAP (500 ng, i.c.v.) significantly increased the chronic tolerance to morphine and enhanced the naloxone (1 mg/kg, s.c.)-precipitated withdrawal jumping. Theophylline (1 mg/kg, i.p.) pretreatment significantly enhanced the effect of PACAP on morphine analgesia but the effects of PACAP on tolerance and withdrawal were unaffected upon theophylline administration. On the grounds of our previous studies with vasoactive intestinal polypeptide (VIP), it appears that different receptors are involved in the effects of PACAP in acute and chronic morphine actions. Our results indicate that PACAP-induced actions likely participate in acute and chronic effects of morphine and suggest a potential role of PACAP in opioid analgesia, tolerance and withdrawal.",
keywords = "Analgesia, Morphine, Mouse, PACAP, Tolerance, Withdrawal",
author = "M{\'o}nika M{\'a}csai and Imre Pataki and G. T{\'o}th and Gyula Szab{\'o}",
year = "2002",
month = "11",
day = "15",
doi = "10.1016/S0167-0115(02)00187-8",
language = "English",
volume = "109",
pages = "57--62",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice

AU - Mácsai, Mónika

AU - Pataki, Imre

AU - Tóth, G.

AU - Szabó, Gyula

PY - 2002/11/15

Y1 - 2002/11/15

N2 - The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice. The heat-radiant tail-flick test was used to assess antinociceptive threshold. Intracerebroventricular (i.c.v.) administration of PACAP alone had no effect on pain sensitivity but in a dose of 500 ng, it significantly diminished the analgesic effect of a single dose of morphine (2.25 mg/kg, s.c.). PACAP (500 ng, i.c.v.) significantly increased the chronic tolerance to morphine and enhanced the naloxone (1 mg/kg, s.c.)-precipitated withdrawal jumping. Theophylline (1 mg/kg, i.p.) pretreatment significantly enhanced the effect of PACAP on morphine analgesia but the effects of PACAP on tolerance and withdrawal were unaffected upon theophylline administration. On the grounds of our previous studies with vasoactive intestinal polypeptide (VIP), it appears that different receptors are involved in the effects of PACAP in acute and chronic morphine actions. Our results indicate that PACAP-induced actions likely participate in acute and chronic effects of morphine and suggest a potential role of PACAP in opioid analgesia, tolerance and withdrawal.

AB - The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice. The heat-radiant tail-flick test was used to assess antinociceptive threshold. Intracerebroventricular (i.c.v.) administration of PACAP alone had no effect on pain sensitivity but in a dose of 500 ng, it significantly diminished the analgesic effect of a single dose of morphine (2.25 mg/kg, s.c.). PACAP (500 ng, i.c.v.) significantly increased the chronic tolerance to morphine and enhanced the naloxone (1 mg/kg, s.c.)-precipitated withdrawal jumping. Theophylline (1 mg/kg, i.p.) pretreatment significantly enhanced the effect of PACAP on morphine analgesia but the effects of PACAP on tolerance and withdrawal were unaffected upon theophylline administration. On the grounds of our previous studies with vasoactive intestinal polypeptide (VIP), it appears that different receptors are involved in the effects of PACAP in acute and chronic morphine actions. Our results indicate that PACAP-induced actions likely participate in acute and chronic effects of morphine and suggest a potential role of PACAP in opioid analgesia, tolerance and withdrawal.

KW - Analgesia

KW - Morphine

KW - Mouse

KW - PACAP

KW - Tolerance

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0037111161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037111161&partnerID=8YFLogxK

U2 - 10.1016/S0167-0115(02)00187-8

DO - 10.1016/S0167-0115(02)00187-8

M3 - Article

C2 - 12409215

AN - SCOPUS:0037111161

VL - 109

SP - 57

EP - 62

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -